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Abstract. Dishevelled (Dvl) proteins are important regulators of the Wnt signalling pathway, interacting
through their PDZ domains with the Wnt receptor Frizzled. Blocking the Dvl PDZ–Frizzled interaction rep-
resents a potential approach for cancer treatment, which stimulated the identification of small-molecule in-
hibitors, among them the anti-inflammatory drug Sulindac and Ky-02327. Aiming to develop tighter binding
compounds without side effects, we investigated structure–activity relationships of sulfonamides. X-ray crystal-
lography showed high complementarity of anthranilic acid derivatives in the GLGF loop cavity and space for
ligand growth towards the PDZ surface. Our best binding compound inhibits Wnt signalling in a dose-dependent
manner as demonstrated by TOP-GFP assays (IC50 ∼ 50 µM) and Western blotting of β-catenin levels. Real-
time PCR showed reduction in the expression of Wnt-specific genes. Our compound interacted with Dvl-1 PDZ
(KD = 2.4 µM) stronger than Ky-02327 and may be developed into a lead compound interfering with the Wnt
pathway.
1 Introduction
Dishevelled (Dvl) proteins comprise 500 to 600 amino acids
and contain three conserved domains: an N-terminal DIX
(Dishevelled/Axin) domain (Schwarz-Romond et al., 2007;
Madrzak et al., 2015), a central PDZ (PSD95/Dlg1/ZO-
1) domain (Doyle et al., 1996; Ponting et al., 1997), and
a C-terminal DEP (Dishevelled/Egl-10/Pleckstrin) domain
(Wong et al., 2000; Wallingford and Raymond, 2005). Dvl
transduces Wnt signals from the membrane receptor Frizzled
to downstream components via the interaction between Dvl
PDZ and Frizzled (Wong et al., 2003); thus, it has been pro-
posed as a drug target (Klaus and Birchmeier, 2008; Holland
et al., 2013; Polakis, 2012). Several studies identified internal
peptides of the type KTXXXW as well as C-terminal pep-
tides of the type 8GWF in which  is any aromatic amino
acid (F, W, or Y) as Dvl PDZ targets (Lee et al., 2009a; Zhang
et al., 2009). Three Dvl homologues, Dvl-1, Dvl-2, and Dvl-
3, have been identified in humans. Sequence identity is 88 %
between Dvl-3 PDZ and Dvl-1 PDZ and 96 % between Dvl-3
PDZ and Dvl-2 PDZ (Fig. S1 in the Supplement). Dvl pro-
teins are found to be upregulated in breast, colon, prostate,
mesothelium, and lung cancers (Weeraratna et al., 2002; Ue-
matsu et al., 2003a, b; Bui et al., 1997; Mizutani et al., 2005).
PDZ domains appear in 440 copies spread over more than
260 proteins of the human proteome (Ponting et al., 1997).
They maintain relatively specific protein–protein interactions
and are involved, for example, in signalling pathways, mem-
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brane trafficking, and in the formation of cell–cell junctions
(Zhang and Wang, 2003; Fanning and Anderson, 1996; Ku-
rakin et al., 2007). Hence, they are potentially attractive drug
targets (Rimbault et al., 2019; Christensen et al., 2020). PDZ
domains consist of about 90 amino acids which fold into
two α-helices and six β-strands exposing a distinct peptide-
binding groove (Doyle et al., 1996; Lee et al., 2017). The
conserved carboxylate-binding loop (GLGF loop, FLGI in
Dvl-2, and -3, Fig. 1) is essential for the formation of a hy-
drogen bonding network between the PDZ domain and PDZ-
binding C-terminal peptide motifs, in most cases coordinat-
ing the C-terminal carboxylate group of the interaction part-
ner. In the respective complexes, the C-terminal residue of
the ligand is referred to as P0; subsequent residues towards
the N-terminus are termed P−1, P−2, and P−3, etc. Previous
studies have revealed that P0 and P−2 are most critical for
PDZ-ligand recognition (Songyang et al., 1997; Schultz et
al., 1998).
PDZ domains are divided into at least three main classes
on the basis of their amino acid preferences at these two sites:
class I PDZ domains recognize the motif S/T-X-8-COOH (8
is a hydrophobic residue, and X is any amino acid), class II
PDZ domains recognize the motif 8-X-8-COOH, and class
III PDZ domains recognize the motif X-X-COOH. How-
ever, some PDZ domains do not fall into any of these spe-
cific classes (Pawson, 2007; Sheng and Sala, 2001; Zhang
and Wang, 2003). The Dvl PDZ domains, for example, rec-
ognize the internal sequence KTXXXW within the Frizzled
peptide 525(GKTLQSWRRFYH)536 (KD ∼ 10 µM) (Wong
et al., 2003; Chandanamali et al., 2009).
Due to their occurrence in important proteins, PDZ
domains received early attention as drug targets, which
has been nicely summarized in Christensen et al. (2019).
There are several examples of Dvl PDZ inhibitors of
a peptide or peptidomimetic nature (e.g. Hammond et
al., 2006; Haugaard-Kedstrom et al., 2021), including
peptide conjugates (e.g. Qin et al., 2021; Hegedüs et
al., 2021) and on an organic small-molecule basis. The
latter approach is considered most beneficial in long-term
medical treatments of conditions like cancer or neurological
disorders. NSC668036 (Shan et al., 2005; Wang et al., 2015)
is a peptide-mimic compound which interferes with Wnt
signalling at the Dvl level. Based on a computational phar-
macophore model of NCS668036, additional compounds
were later reported (Shan et al., 2012). Known as the first
non-peptide inhibitor, the 1H-indole-5-carboxylic acid
derivative FJ9 (Fujii et al., 2007) showed therapeutic poten-
tial. Further examples including Sulindac (Lee et al., 2009b),
2-((3-(2-phenylacetyl)amino)benzoyl)amino)benzoic acid
(3289-8625, also called CalBioChem(CBC)-322338)
(Grandy et al., 2009; Hori et al., 2018), N-benzoyl-2-amino-
benzoic acid analogues (Hori et al., 2018), phenoxyacetic
acid analogue (Choi et al., 2016), and ethyl 5-hydroxy-1-
(2-oxo-2-((2-(piperidin-1-yl)ethyl)amino)ethyl)-1H-indole-
2-carboxylate (KY-02327) (Kim et al., 2016) have been
reported, with the last one showing the highest in vitro
affinity (8.3 µM) of all. Despite the existence of the above-
mentioned inhibitors of Dvl PDZ, the development of
tighter-binding non-peptidic small-compound modulators of
the respective functions, binding with nanomolar affinity, is
necessary and remains challenging. On this path, we explore
optimal fits for the primary binding pocket by cycles of
chemical synthesis and X-ray crystallography and explore
further avenues for systematically growing ligands along the
Dvl PDZ surface to provide structure–activity relationship
(SAR) for the development of inhibitors in the low or
medium nanomolar range. Nuclear magnetic resonance
(NMR) spectroscopy was used to detect primary hits and for
follow-up secondary screening. The ability of NMR to detect
weak intermolecular interactions (µM<KD <mM) makes
it an ideal screening tool for identifying and characterizing
weakly binding fragments, to be optimized subsequently by
chemical modification in order to improve binding (Zartler
and Shapiro, 2006; Shuker et al., 1996; Zartler et al., 2003).
Besides NMR, the determination of X-ray crystal structures
of selected complexes was fundamental for further design of
new compound structures with improved binding. In the first
round of screening, a library constructed after computational
docking of candidates into the peptide binding site of the
Dvl PDZ domains was investigated, followed by secondary
screening utilizing a library of 120 compounds containing
rhodanine or pyrrolidine-2,5-dione moieties.
2 Results and discussion
2.1 PDZ targeted library design
The PDZ targeted library was designed to cover all PDZ do-
mains with available structure. For this, all X-ray- and NMR-
derived PDZ structures were retrieved from the PDB, clus-
tered, and six selected centroids were subjected to the virtual
screening routine. The area considered is shown in Fig. 1a,
with the blue sphere indicating the geometrical centre. The
clustering of the PDZ domains was performed according to
the shapes of their binding sites rather than backbone confor-
mation. This approach accounts for the importance of surface
complementarity of protein–small-molecule interactions and
the critical contribution of van der Waals interactions to the
binding free energy. On the other hand, PDZ domains have
evolved to recognize a carboxyl group that is mostly derived
from the C-terminus of natively binding proteins. Finally,
the fact that PDZ can recognize internal motifs (Hillier et
al., 1999), including KTXXXW of Frizzled-7 recognized by
Dvl PDZ (Wong et al., 2003; Chandanamali et al., 2009),
raises the question of what are key binding contributions with
PDZ domains: negative charge, hydrogen bonding, or shape
complementarity (Harris et al., 2003). For this reason, tangi-
ble compounds were preselected to have extensive hydropho-
bic contacts as well as chemical groups that mimic the car-
boxylic group.
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Virtual screening was performed with QXP (McMartin
and Bohacek, 1997), and the generated complexes were se-
quentially filtered with a self-designed MultiFilter algorithm.
From the resulting 1119 compounds a randomly selected set
of 250 compounds was subjected to NMR validation.
2.2 NMR screening and development of compounds
The results of virtual screening were checked experimen-
tally by comparing 2D 1H−15N HSQC (heteronuclear sin-
gle quantum correlation) spectra of Dvl-3 PDZ in the ab-
sence and presence of the compound to elucidate ligand-
induced changes of chemical shifts. Chemical shift perturba-
tion differences (1CSP, representing the average of the three
strongest shifting cross peaks according to Eq. 1) were eval-
uated in cases where the residues responding strongest are
inside the area defined by Fig. 1a. The responses were clas-
sified into (i) inactive compounds (1CSP< 0.02); (ii) very
weak interactions (0.02≤1CSP≤ 0.05); (iii) weak inter-
actions (0.05<1CSP≤ 0.1); (iv) intermediate interactions
(0.1<1CSP≤ 0.2); (v) strong interactions (0.2<1CSP≤
0.5), and (vi) very strong interactions (1CSP> 0.5). In most
cases, the signals of residues S263, V287, and R320 (Fig. 1a)
within the conserved binding site were most strongly per-
turbed (Fig. S2). With the1CSP of 0.12 ppm, the isoleucine-
derived compound 1 ((2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)sulfonyl)-L-isoleucine containing a sulfonamide moiety
was detected initially as one of the best “hits” according to
chemical shift changes. The sulfonamide is a well-known
moiety in drug discovery (Mathvink et al., 1999; Wu et
al., 1999; Sleight et al., 1998; O’Brien et al., 2000; Tellew
et al., 2003).
Upon NMR titration experiments for compound 1
(Fig. S2) with Dvl-3 PDZ, the largest chemical shift pertur-
bations were observed for S263 in strand βB and R320 in
helix αB of Dvl-3 PDZ, confirming the conserved binding
site.
By comparing the binding of several sulfonamide com-
pounds in a secondary screening event and making use of
our in-house library, four new compounds (2, 3, 4, 5) that in-
duced chemical shift perturbations larger than 0.2 ppm were
found (for binding constants see Table 1) and considered
further as reasonably strong binders. The similarity of the
structures led us to define Scheme 2 as a scaffold for further
refinements. Sulfonamides were considered more drug-like
and hence followed up at higher priority than other hits. We
realized that our four new compounds had different moieties
at R2 in combination with a small R1 (fluorine). A decrease
of binding was observed with decreasing size of R2.
In order to assess the importance of the aryl group at
R2 for complex formation, it was replaced by a methyl
group as substituent to yield compound 6, which showed
a drastic decrease of binding (Table 1). Compounds 3, 4,
and 5 did not distinguish between the Dvl-3 PDZ and Dvl-
1 PDZ. In order to obtain detailed insight into the bind-
ing mode of these compounds, crystal structures of Dvl-3
PDZ in complex with compounds 3, 5, and 6 were deter-
mined (Fig. 1). For compound 3, the crystal structure re-
vealed two complexes within the crystallographic asymmet-
ric unit (AU) at 1.43 Å resolution. Both show the anthranilic
acid with the attached fluorine pointing into the hydrophobic
binding pocket (Figs. 1b and S3a), while the carboxyl group
forms a hydrogen-bond network with amide residues of the
carboxylate binding loop, in particular strand βB (Fig. 1b)
and specifically with residues I262, G261, and L260. The
two sulfonamide oxygen atoms form hydrogen bonds with
R320 and H324 (weak) of helix αB for only one complex
in the AU. The aromatic aryl group (tetrahydronaphtalene)
attached to the sulfonamide is involved in hydrophobic in-
teractions with F259 were (Fig. S3b). The 1.6 Å complex
structure with compound 5 (four molecules per AU) exhibits
a comparable binding mode as found for compound 3 with
a hydrogen-bond network involving the carboxyl group and
the amides of I262, G261, L260, and of the sulfonamide to
H324 (Fig. 1c). No hydrogen bond was observed to R320 in
all four molecules of the AU, but small variations of the aryl
moiety relative to F259 (Fig. S3c). The crystals of the com-
plex with 6 show two molecules in the AU (Fig. 1d). The
sulfonamide is bound by H324 in both complexes (Fig. S3d).
However, compound 6 bound only in the millimolar (mM)
range as compared to 3 and 5, which obviously results from
the missing aromatic rings.
To further explore the importance of the fluorine site in-
side the hydrophobic pocket, substitutions by bromine, chlo-
rine, methyl, and trifluoromethyl were chosen. In fact, the
methyl group has a similar van der Waals (vdW) radius as
the CF3 group. Iodine was not considered a good candi-
date since it increases molecular weight substantially, and
the compounds may be chemically less stable, in particular
in biological assays. Taking into account that compound 6
did not bind because of the missing aromatic ring at the R2
position, our overall strategy was to increase the aromatic
ring at R2 while finding a good fit for R1, keeping an eye on
the molecular weight to enable further compound modifica-
tions that fulfil key properties as defined by Lipinski (2000)
and Lipinski et al. (1997). Our preference to continue explo-
ration at the R1 position of the aromatic ring in Scheme 1
was inspired by the absence of hits with other substitutions
in the secondary screening event and the initial X-ray struc-
tures that showed a hydrophobic pocket available for sub-
stituents in this position, while other sites at the aromatic ring
would include steric hindrance. Therefore, compounds 7–17
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Scheme 1. Compounds 2, 3, 4, and 5.
Scheme 2. Basic fragment for further synthesis.
were obtained and were classified in three different groups
to derive structure–activity relationships (SARs). The com-
pounds 7–10 in group 1 contain different R1 (Br, CF3, Cl,
CH3) but the same moiety (tetrahydronaphthalene) at R2. As
expected, binding could be further improved by displace-
ment of the fluorine with elements exhibiting larger vdW
radii. Indeed, the KD decreased stepwise, and the best fit
was observed for compound 8 containing a trifluoromethyl
group (KD = 17.4 µM for Dvl-3 PDZ and 24.5 µM for Dvl-
1 PDZ). The different substituents at the R1 position con-
tribute to an increased binding affinity in the following or-
der: F< Cl< Br< CF3 (compound 3< 9< 7< 8, respec-
tively). Compound 10 with a methyl group at the R1 posi-
tion showed only marginally improved binding, although the
methyl group has a similar vdW radius as the CF3 group of
compound 8. The difference in binding results most likely
from their different hydrophobicity.
The 1.85 Å crystal structure of the Dvl-3 PDZ domain with
compound 7 (KD = 20.6 µM for Dvl-3 PDZ and 18.2 µM for
Dvl-1 PDZ) showed an identical hydrogen-bond network in-
volving the amide groups of residues I262, G261, and L260
of the carboxyl binding loop as seen for all other complex
structures reported here (Fig. 1e). Only one hydrogen bond
between the sulfonamide and R320 was found in addition for
one of the two Dvl-3 PDZ molecules per AU. H324 of Dvl-3
PDZ was not addressed by the sulfonamide as seen previ-
ously. The bromine at position R1 points into the hydropho-
bic pocket, which is similar as the fluorine in the complex
structure with compound 3. The two complexes in the AU
show significant variations in the positions of the tetrahy-
dronaphtalene rings as well as for the side chain of F259 and
R320 (Fig. S3e).
Following the analysis of the complex involving com-
pound 7, the binding characteristics of the group-2 com-
pounds (11–14) were investigated. They contain bromine as
R1 and different substituents at the R2 position to assess the
importance of π–π stacking interactions involving F259. KD
values of 7.2 µM for compound 13 and 13.8 µM for com-
pound 11 were found with respect to the interaction with
Dvl-3 PDZ. Crystal structures of Dvl-3 PDZ in complex with
compound 11 (1.58 Å resolution, 1 molecule per AU) and
12 (1.48 Å, 2 molecules per AU) revealed very similar bind-
ing as observed in the crystal structures with compounds 3
and 7. The aromatic rings at R2 show hydrophobic interac-
tions to F259 but not a classical π–π stacking as expected.
Nevertheless, the tighter binding of compound 11 could be
explained by the larger aromatic substituent at the R2 po-
sition compared to compound 12. Both complex structures
show also non-specifically bound ligands in crystal contacts
(Fig. S3h, Tables S2 and S3 in the Supplement). The addi-
tional ligand molecules in both complex structures can be ex-
plained as a crystallographic artefact, which is verified with
ITC experiments that indicate 1 : 1 stoichiometries in both
cases (Fig. S5). With respect to the selectivity of the tested
compounds, we observed a 6- to 30-fold stronger binding of
compounds 7, 9, 11, and 13 to Dvl-3 PDZ as compared to
Dvl-1 PDZ. These differences are related to the different se-
quences at the end of αB. Most importantly, H324 is replaced
by a serine residue in the Dvl-1 PDZ domain.
The group-3 compounds (15–17) contain a trifluoromethyl
at position R1 and were tested to investigate a cooperative
role of this moiety with various substituents at position R2.
All compounds bind weaker to Dvl-1 and Dvl-3 than com-
pound 8 which contains tetrahydronaphthalene at the R1 po-
sition, revealing its important role in the interaction.
2.3 Further modifications towards higher affinity and
reduced toxicity
Possible cytotoxic effects of compounds 3, 7, 8, 9, and 10
were evaluated in cell viability assays using HEK293 cells
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Table 1. Binding constants KD (µM) of Dvl-3 PDZ and Dvl-1 PDZ for compounds 3–21 derived by ITC or NMR if not specified. The KD
values determined by NMR are reported as means ± standard deviations of measurements evaluating shifts of cross peaks of at least six
residues influenced upon binding of the ligand. The KD values (1/KA) determined by ITC were obtained as fits to a one-site binding model
(n in the range of 0.95–1.2) with KD errors obtained by 1KA/KA2.
ID R1 R2 (KD, µM) (KD, µM)
Dvl-3 PDZ Dvl-1 PDZ
3 F 80.6± 6.1NMR 112.7± 25.9NMR
4 F 83.9± 7.8NMR 114.4± 9.8NMR
5 F 140.6± 14.1NMR 160.1± 14.6NMR
6 F CH3 > 1000ITC –
7 Br 20.6± 2.4NMR 18.2± 2.4NMR
8 CF3 17.4± 0.5ITC 24.5± 1.5ITC
9 Cl 41.1± 3.1NMR 45.6± 4.5NMR
10 CH3 62.5± 4.7NMR 60.5± 5.3NMR
11 Br 13.8ITC 119.9ITC
12 Br 58.5ITC nd
13 Br 7.2ITC 213.2ITC
14 Br 58.1± 2.1ITC nd
15 CF3 52.9± 1.7ITC nd
16 CF3 59.1± 1.5ITC nd
17 CF3 49.5ITC nd
18 CH3 9.4± 0.6ITC 2.4± 0.2ITC
19 CH3 21.8± 1.7ITC 8.0± 0.5ITC
20 CH3 9.8± 0.3ITC 4.7± 0.3ITC
21 CH3 12.5± 0.5ITC 4.7± 0.2ITC
nd: not determined.
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Figure 1. (a) Definition of PDZ binding site. The centre of the binding site (blue sphere) is defined as the geometric centre of Cα atoms (red
spheres) of seven residues (typed in red) defined by multiple sequence alignment. (b–h) Magnified views into crystal structures of various
compounds bound to the Dvl-3 PDZ domain. The 2Fo-Fc electron density around the compounds is shown at 1σ contour level, and the dotted
lines indicate formed hydrogen bonds. In the bound compounds covalent bonds to carbon atoms are shown as green sticks. Important residues
involved in compound binding are labelled and displayed in atom colours (carbons blue or dark yellow). Panels (b–d) show compound 3,
5, and 6, respectively. All compounds in (b–d) contain fluorine (light blue) in para position to the amine. Panels (e–g) represent the bound
compounds 7, 11, and 12, respectively. All have bromine (dark red) in para position to the amine. Panel (h) shows compound 18 within the
binding site. The accession codes of the structures (b–h) are 6ZBQ, 6ZBZ, 6ZC3, 6ZC4, 6ZC6, 6ZC7, and 6ZC8, respectively.
(Fig. S4). These compounds were selected due to differ-
ent substituents at the R1, including halogens. Cell viability
was measured 24 h after treatment with the individual com-
pounds, and half maximal inhibitory concentrations (EC50)
were calculated for each compound. The compounds exhib-
ited EC50 values in the range of 61–131 µM (Fig. S4a). Com-
pounds 3 and 10 that contained fluorine or methyl group
substituents at R2, respectively, were the least toxic, while
compound 7, containing bromine, was the most toxic. The
results from crystallography, modelling studies, and of the
cell proliferation assays led us to further investigate com-
pounds 18–21 that contain a methyl group at the R1 posi-
tion and different substituents as R2. In this way, we aimed
to develop both potent and less-toxic cell-permeable in-
hibitors. All compounds showed strong interactions as in-
dicated by chemical shift perturbation values between 0.30
to 0.34 ppm (Table S1). The binding constants were evalu-
ated by ITC whereby compound 18 (KD = 9.4 µM for Dvl-3
PDZ and 2.4 µM for Dvl-1 PDZ) appeared to be most po-
tent. Compound 18 contains a pyrazole ring which is con-
sidered an important biologically active heterocyclic moiety
(Lv et al., 2010). Compounds 20 (KD = 9.8 µM for Dvl-3
PDZ and 4.7 µM for Dvl-1 PDZ) and 21 (KD = 12.5 µM for
Dvl-3 PDZ and 4.7 µM for Dvl-1 PDZ) contain pyrrole rings.
Their binding constants almost have the same value despite
the different substituents (bromine or chlorine) at the pyrrole
rings. The binding of compounds 18–21 to both Dvl PDZ
domains is mainly enthalpy-driven as indicated in Table 2,
with a slightly stronger effect for Dvl-1 PDZ than for Dvl-3
PDZ. To our surprise, the crystal structure of Dvl-3 PDZ in
complex with compound 18 shows the pyrazole substituent
in the R2 position orientated away from the binding pocket.
Instead, a π–π stacking interaction with F259 was observed
(Fig. S3i). Cytotoxicity of 18–21 was determined via MTT
assays (Mosmann, 1983) that displayed viability up to con-
centrations above 150 µM (Fig. S4b).
2.4 Comparison to reported Dvl PDZ-binding molecule
subsection
Our compounds bind to Dvl-3 with a KD better than
10 µM (and slightly tighter to Dvl-1, see Table 2) with
18 showing a KD of 2.4 µM and chemical shift changes
indicating binding to the canonical binding site (Fig. 1a).
For comparison, four compounds of those shown in
Fig. S6 were assayed by ITC (Fig. S7), regarding their
affinity to Dvl-3 PDZ. Ky-02327 was already determined
to bind with a KD of 8.3± 0.8 µM (Kim et al., 2016)
to Dvl-1 PDZ. Our first interest was oriented towards
sulfonamides. Hori et al. (2018) have recently reported 3-
({3-[(2-carboxyphenyl)sulfamoyl]phenyl}sulfamoyl)benzoic
acid (NPL-1011) binding to Dvl-1 PDZ via the detection of
chemical shift changes and further sulfonamide compounds
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Table 2. Isothermal titration calorimetric data for the reaction between Dvl-3 PDZ; Dvl-1 PDZ; and our compounds 18, 19, 20, and 21.
Compounds NPL-1011 (Hori et al., 2018), Sulindac (Lee et al., 2009), CBC-322338/3289-8625 (Grandy et al., 2009; Hori et al., 2018), and
NSC668036 (Shan et al., 2005) are also given; for more thermodynamic parameters, see Fig. S7. For Ky-02327, the value from literature is
included.
Compound Dvl-3 PDZ Dvl-1 PDZ
KD 1H T1S 1G KD 1H T1S 1G
(µM) (kcal mol−1) (µM) (kcal mol−1)
18 9.4± 0.6 −8.0 −1.2 −6.7 2.4± 0.2 −12.2 −4.7 −7.5
19 21.0± 1.7 −5.9 0.4 −5.5 8.0± 0.5 −7.3 −0.3 −7.0
20 9.8± 0.3 −10.4 −3.6 −6.8 4.7± 0.3 −9.4 −2.2 −7.2
21 12.5± 0.5 −5.9 0.7 −6.8 4.7± 0.2 −8.5 −1.5 −7.0
NPL-1011 79.7± 53.3
Sulindac 8.3± 2.5
CBC-322338/3289-8625 > 400 µM
NSC668036 > 400 µM
Ky-02327 8.3± 0.8
that showed smaller effects, indicating weaker binding. We
examined the binding constant of NPL-1011 which pos-
sesses two sulfonamide moieties by ITC and found a value
of 79.7± 53.3 µM (see Table 2). For further comparisons,
we assayed also CBC-322338/3289-8625, Sulindac, and
NSC668036 by ITC. Surprisingly, CBC-322338/3289-8625
showed very low affinity, with a KD above 400 µM in our
ITC assay, in line with the value found by Hori et al. (2018)
(954± 403 µM). We also applied an NMR shift assay
(Fig. S8), yielding a 1CSP around 0.1. Based on NMR and
ITC studies, the binding affinity of CBC-322338/3289-8625
to Dvl-3 seems to be less than 50 µM (comparing the CSPs
from the NMR assay with those of our other compounds
listed in Table S1 and the respective binding constants in
Table 1, considering also the weak heat development in our
ITC assay), which was larger than the originally reported
value (10.6± 1.7) (Grandy et al., 2009) that was obtained
with a different method. Concerning non-sulfonamide
compounds, a KD of 8.3±2.5 µM was detected for Sulindac,
while NSC668036 (Shan et al., 2005) did not show high-
affinity binding. These results are largely in agreement with
literature. In all cases, compounds were tested for purity
after KD measurements (see Fig. S9a–d).
2.5 Selectivity testing using a set of selected PDZ
domains
Compounds 18, 20, and 21 were tested towards other PDZ
domains for selectivity. The set included PSD95-PDZ 2 and
3, Shank-3, α-syntrophin, and AF-6 PDZ. According to the
determined chemical shift perturbations (Table S4), our com-
pounds show no or very weak interactions with the selected
PDZ domains (0.05<1CSP≤ 0.1 ppm). These findings led
to the conclusion that our compounds show considerable se-
lectivity towards Dvl PDZ domains. This selectivity might
be due to a unique feature of Dvl PDZ where R320 (Dvl-3
PDZ) or R322 (Dvl-1 PDZ) is crucial for interactions, ex-
plaining selectivity with respect to other PDZ domains. In
addition, the large hydrophobic cavity for the side chain of
the C-terminal residue of the interacting peptide is occupied
by a large moiety in the case of compounds 18, 20, and 21
which might not be accommodated in most other PDZ do-
mains.
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2.6 Dvl inhibitors antagonize canonical Wnt signalling
and Wnt-related properties of cancer cells
Taking advantage of a lentivirus that encodes GFP in a β-
catenin/TCF-dependent fashion (TOP-GFP, SABiosciences),
a stable HEK293 reporter cell line was established to eval-
uate the inhibitory effect of compounds 18, 20, and 21 on
canonical Wnt signalling activity. TOP-GFP expression in
this cell line was induced by the ligand Wnt3a, which di-
rectly activates the Frizzled–Dishevelled complex and pro-
tects β-catenin from degradation by the destruction complex
(Fig. 2a). Remarkably, all three compounds inhibited Wnt
signalling induced by Wnt3a in a dose-dependent manner
(Fig. 2b), yielding IC50 values between 50–80 µM.
To further evaluate the specificity of our Dvl inhibitors,
the conventional TOPflash (Molenaar et al., 1996) and other
luciferase reporter assays were performed. In HeLa cells, 20
inhibited TOP-luciferase signals stimulated by Wnt3a but not
by CHIR99021 (Sineva and Pospelov, 2010), a compound
that activates Wnt signalling downstream of Dvl (Fig. 2a,
c). Compound 20 had no significant inhibitory effects in re-
porter assays that measure the activity of other signalling
systems, e.g. NF–κB–luciferase stimulated by recombinant
TNFα, Notch–luciferase stimulated by the overexpression of
the Notch intracellular domain, or the Oct–luciferase assay
that is stimulated by overexpression of Oct4 (SABiosciences,
Fig. 2d). These results strongly indicate that 20 is specific for
canonical Wnt signalling at the upstream level.
Increased β-catenin protein level is a hallmark of active
Wnt signalling (Kishida et al., 1999). Once β-catenin is ac-
cumulated in the cytoplasm, it can translocate into the nu-
cleus and activate the transcription of Wnt target genes by
interacting with transcription factors of the TCF/LEF family
(Fig. 2a) (Behrens et al., 1996). In HeLa cells, all three Dvl
inhibitors blocked the increase of production of β-catenin
by Wnt3a in a dose-dependent manner, as seen by Western
blotting (Fig. 2e). Increased mRNA levels of the Wnt target
genes Axin2, LEF1, and Bmp2 (Riese et al., 1997; Jho et
al., 2002; Lewis et al., 2010) were induced by Wnt3a treat-
ment, as measured by qRT-PCR, and these increases were
reduced by compounds 18, 20, and 21 (Fig. 2f). These re-
sults demonstrate that compounds 18, 20, and 21 inhibit Wnt
signalling as indicated by reduced accumulation of β-catenin
and low expression of typical Wnt target genes.
Canonical Wnt signalling contributes to cancer progres-
sion by inducing high motility and invasion of cancer cells
while retaining the self-renewal property of cancer-initiating
cells (Fritzmann et al., 2009; Sack et al., 2011; Vermeulen
et al., 2010; Malanchi et al., 2008). In particular, cancer-
initiating cells are propagated and enriched in non-adherent
sphere culture, demonstrating the self-renewal capacity of
the stem cells (Kanwar et al., 2010; Fan et al., 2011). To
investigate the potential value of the Dvl inhibitors for in-
terfering with these Wnt-related properties of cancer cells,
the sub-line SW480WL was derived from the SW480 colon
cancer cell line, which exhibits a low level of endogenous
Wnt activity (Fang et al., 2012). The cell migration and self-
renewal properties of SW480WL cells were enhanced by
Wnt3a treatment, as revealed by trans-well and sphere for-
mation assays (Fig. 2g, h). Compounds 18 and 20 prevented
increased cell migration and sphere formation. These results
indicate that our Dvl inhibitors may be developed into lead
compounds that interfere with Wnt signalling.
3 Experimental section
3.1 Clustering binding sites and selection of
representative PDZ domains
Three-dimensional structures of PDZ domains were retrieved
from the PDB (Berman et al., 2000). At the time of the study,
from a total of 266 PDB files 126 were NMR solution struc-
tures and 140 were derived from X-ray diffraction studies.
The structures belong to 163 PDZ domains of 117 differ-
ent proteins from 11 organisms. Files which contain more
than one 3D conformation for a domain (up to 50 for NMR-
derived data) were split into separate structures and were
considered independently. The total number of unique 3D
structures was 2708.
Amino acid sequences of PDZ domains were aligned using
Clustal Omega software (Sievers et al., 2011). Based on the
alignment, for each structure, residues which form the bind-
ing site (strand βB and helix αB) were determined (Fig. S8).
The centre of the binding site was defined as a geometric cen-
tre of Cα atoms of seven residues (six residues from the βB
strand and the second residue from the αB helix). Such bias
towards the βB strand was made to cover sites occupied by
residues in −1 and −3 positions.
The triangulated solvent-accessible surface for each PDZ
structure was built using MSMS software (Sanner et
al., 1996) with a spherical probe radius of 1.4 Å and ver-
tex density 10 Å−1. The largest connected set of surface
vertices within 9 Å from the centre of the binding site was
used to construct shape-based numerical descriptors. The de-
scriptors are 508-dimensional vectors of non-negative inte-
ger numbers and were built using a shape distributions ap-
proach (Osada et al., 2002). In total 10 (Pawson, 2007) ver-
tex triplets were selected randomly, each forming a triangle.
Triangles which had a side longer than 16 Å were discarded.
Triangle sides were distributed into 16 length bins, each 1 Å
wide, covering lengths from 0 to 16 Å. A combination of
three sorted side lengths, each belonging to 1 of 16 distance
bins, defines 1 of 508 categories of the triangles. The num-
ber of triangles of each category was calculated, resulting
in a 508-dimensional vector which is used as a numerical
descriptor of the binding pocket shape. For further opera-
tions with descriptors, an Euclidian metric was introduced.
Shape descriptors were distributed into 6 clusters using the
k-means algorithm (Jain and Dubes, 1988). For each cluster,
a centroid structure was defined as the one whose descrip-
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Figure 2. DVL inhibitors antagonize Wnt signalling and Wnt-related properties of cancer cells induced by Wnt3a. (a) Scheme of Wnt
signalling pathway. Important components of the Wnt signalling pathway are schematically presented. Wnt3a treatment increases the tran-
scription of Wnt targets, enhances signals of TOP-GFP and TOPflash assays, and promotes Wnt-related biological properties of cancer cells.
(b) TOP-GFP reporter assays were performed with HEK293 reporter cell line. Compounds 18, 20, and 21 inhibited Wnt3a-induced Wnt ac-
tivation in a dose-dependent manner with IC50 of 50–75 µM. (c, d) TOPflash assays stimulated with Chir99021 and reporter assays of other
pathways were used to evaluate the specificity of compound 20. Compound 20 specifically inhibited Wnt3a-induced Wnt activation and had
no or a mild effect on Chir99021-induced Wnt activation and other signalling pathways including NF–κB, Notch, and Oct4. (e) β-Catenin
protein levels were detected with Western blotting in HeLa cells. Compounds 18, 20, and 21 (150 µM) inhibited accumulation of β-catenin
in HeLa cells treated with Wnt3a. (f) The mRNA levels of Wnt target genes (Axin2, LEF1, and Bmp2) in HeLa cells were measured with
quantitative real-time PCR. Compounds 18, 20, and 21 (150 µM) reduced the transcription of Wnt target genes that are enhanced by Wnt3a
treatment in HeLa cells. (g) Cell migration of SW480 cells after Wnt3a treatment was assessed by trans-well assays. Compounds 18 and
20 (50–100 µM) reduced the migration of SW480 cells enhanced by Wnt3a. (h) SW480 cells were cultured in serum-free non-adherent
conditions to evaluate the self-renewal property enhanced by Wnt3a treatment. Compounds 18 and 20 (25–50 µM) reduced sphere formation
of SW480 cells that was enhanced by Wnt3a treatment. For all tests, three independent biological replicas were performed and error bars
represent standard deviations. P values were calculated from t test. ∗: P < 0.05; ∗∗: P < 0.01; ∗∗∗: P < 0.001.
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tor is the closest to mean descriptor for the cluster. The cen-
troid structures 2O2T#B.pdb, 1VA8#3.pdb, 2DLU#01.pdb,
1UHP#8.pdb, 2OS6#8.pdb, and 3LNX#A.pdb were used for
docking.
3.2 PDZ targeted library design
Screening collection by Enamine Ltd. (Chuprina et
al., 2010), containing a total of 1 195 395 drug-like com-
pounds, was used as the primary source of small molecules.
The natural ligand of PDZ is the C-terminus of a peptide with
carboxylic group making an extensive hydrogen-bond net-
work with the “8G8” motif. Since the carboxyl group pro-
vides either a negative charge or a hydrogen-bond acceptor,
we want our ligands to retain at least one of these features.
Therefore, we pre-filtered the stock library to bear chemi-
cal groups which have negatively charged and/or hydrogen-
bond acceptor functionality. In total 65 288 compounds were
selected for the virtual screening study. The selected six cen-
troids of PDZ domains and the prepared compound set were
subjected to high-throughput docking using the QXP/Flo
software (McMartin and Bohacek, 1997). Complexes were
generated with 100 steps of sdock + routine, and 10 confor-
mations per complex were saved.
Processing of docking poses started with filtering by con-
tact term Cntc from the QXP/Flo scoring function. Entries
with Cntc< 45 were discarded, which removed complexes
with weak geometries of bound ligands. The remained fil-
tering was performed with the in-house MultiFilter program
that allows for flexible geometry-based filtering. We applied
two algorithms, nearest-atom filter and hydrogen-bond filter.
The former filters complexes by distance from a given pro-
tein atom to the nearest heavy ligand atom, while in the latter
filtering is based upon the number of hydrogen bonds calcu-
lated for a given complex geometry. With the nearest-atom
routine we selected compounds that filled the P0 pocket and
sterically mimicked binding of a peptide carboxylic group.
Peptide group hydrogens of the “8G8” motif and atoms
forming the hydrophobic pocket were used for that. With the
hydrogen-bond filter we selected compounds that formed ex-
tensive hydrogen bonding with the PDZ domain. Both these
properties might have larger impact on binding rather than
negative charge (Harris et al., 2003). Details on atoms used
for filtering and thresholds for hydrogen-bond filtering, as
well as the resulting number of compounds, are provided in
Table S5. Compounds from complexes which passed through
these filters were incorporated into a targeted library for the
PDZ-domain family. The final library contained 1119 com-
pounds in total.
3.3 Screening of compounds
Two-dimensional 1H−15N HSQC spectra were used to
screen a library of 212 compounds designed by the com-
pany Enamine for PDZ domains. 50 µM of 15N-labelled pro-
tein samples was prepared in a 20 mM sodium phosphate
buffer, containing 50 mM sodium chloride, 0.02 % (w/v)
NaN3, at pH 7.4. Stock solutions of small molecules were
prepared in DMSO-d6 at a concentration of 160 mM. A
1H−15N HSQC spectrum of Dvl PDZ was acquired at 300 K
with 5 % DMSO-d6 in the absence of ligand as reference
spectrum. Mixtures of 16 compounds were added to 15N-
labelled Dvl PDZ at eightfold molar excess each. The final
concentration of DMSO-d6 in the protein–ligand solutions
was 5 %. Spectra were acquired with eight scans and 256
points in the indirect dimension. Compound binding was de-
duced if the resonance position of a cross peak was signifi-
cantly shifted compared to the reference spectrum. The active
compound was obtained through successive deconvolution.
Experiments were recorded on a Bruker DRX600 spectrom-
eter equipped with a triple-resonance cryoprobe. The prepa-
ration of samples was done automatically by a Tecan Gen-
esis RSP 150 pipetting robot. Spectra were analysed using
the programs TOPSPIN and SPARKY (Goddard and Kneller,
2003).
3.4 Synthesis of compounds
All reagents and starting materials were purchased from
Sigma-Aldrich Chemie, ABCR, Alfa Aesar, or Acros Or-
ganics and used without further purification. All air or
moisture-sensitive reactions were carried out under dry ni-
trogen using standard Schlenk techniques. Solvents were re-
moved by evaporation on a Heidolph Laborota 4000 with
vacuum provided by a PC 3001 Vaccubrand pump. Thin-
layer chromatography (TLC) was performed on plastic-
backed plates pre-coated with silica gel 60 F254 (0.2 mm).
Visualization was achieved under an ultraviolet (UV) lamp
(254 and 366 nm). Flash chromatography was performed us-
ing J.T Baker silica gel 60 (30–63 µm). Analytical high-
performance liquid chromatography (HPLC) was performed
on a Shimadzu LC-20 (degasser DGU-20A3, controller
CBM-20A, autosampler SIL-20A) with a DAD-UV detector
(SPD-M20A), using a reverse-phase C18 column (Nucleo-
dur 100-5, 5 µM, 250 mm×4 mm, Macherey-Nagel, Düren,
Germany). Separation of compounds by preparative HPLC
was performed on a Shimadzu LC-8A system equipped
with a UV detector (SPD-M20A), using a semi-preparative
C18 column (Nucleodur 100-5, 5 µM, 250 mm×10 mm,
Macherey-Nagel) or preparative C18 column (Nucleodur
100-5, 5 µM, 250 mm×21 mm, Macherey-Nagel). The de-
tection wavelength was 254 nm. Gradients of acetonitrile–
water with 0.1 % TFA were used for elution at flow rates of 1,
8, and 14 mL min−1 on the analytical, semi-preparative, and
preparative columns, respectively. Melting point (mp) val-
ues were determined with a Stuart melting point apparatus,
SMP3, and are not corrected. Mass spectra were recorded on
a 4000Q TRAP LC–MS–MS system for AB Applied Biosys-
tems MDS SCIEX. NMR spectra were recorded on a Bruker
AV300 spectrometer instrument operating at 300 MHz for
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proton frequency using DMSO-d6 solutions. Chemical shifts
were quoted relative to the residual DMSO peak (1H: δ =
2.50 ppm, 13C: δ = 39.52 ppm). Coupling constants (J) are
given in hertz (Hz). Splitting patterns are indicated as fol-
lows: singlet (s), doublet (d), triplet (t), quartet (q), multiple
(m), and broad (b). Purity of each compound used for biolog-
ical testing was ≥ 95 % unless otherwise noted. The purity
checks of known inhibitors purchased for comparison with
our compounds are found in Fig. S9.
3.4.1 Synthesis of compounds 8, 11–17
To a solution of anthranilic acid substituted with the appro-
priate R1 (1.32 mmol) and sodium carbonate (3.17 mmol) in
water (2 mL) at 80 ◦C, the sulfonyl chloride (1.58 mmol) sub-
stituted with the appropriate R2 was added over a period of
5 min. The stirring continued for 18 h at 80 ◦C. The reac-
tion mixture was cooled to room temperature and acidified
with 6 N HCl, and the resulting solid precipitate was filtered,
washed with water, and dried to give the crude product. The





(0.52 g, 74 % yield) 1H-NMR (300 MHz, DMSO-d6): δ =
11.77 [s, 1H, COOH], 8.13 [s, 1H, NH], 7.85 [d, 4J6,4 =
2.1 Hz, 1H, 6-HAr] 7.62 [d, 4J1′,3′ = 2.1 Hz, 1H, 1’-HAr] 7.53
[dd, 3J4,3 = 7.1 Hz, 4J4,6 = 2.1 Hz, 4-HAr] 7.36 [dd, 3J3′4′ =
7.5 Hz, 4J3′,1′ = 2.4 Hz, 1H, 3’-HAr] 7.15 [d, 3J4′,3′ = 7.5 Hz,
1H, 4’-HAr], 6.90 [d, 3J3,4 = 7.1 Hz, 1H, 3-HAr] 2.73 (m,
4H, CH2); 1.6 (m, 4H, CH2). 13C-NMR (75 MHz, DMSO-
d6): δ = 169.1(C, CAr-8], 152.7(C, CAr-2), 143.8 (C, CAr-
4a’), 138.7(C, CAr-2’), 135.9 (C, CAr-8a’), 130.4(CH, CAr-
4), 128.7 (CH, CAr-6), 127.5 (CH, CAr-1’), 124.0 (CH, CAr-
4’), 121.6 (C, C-6), 118.2 (C, CAr-5), 116.9 (C, CAr-3), 29.0
(CH2, C-8’), 28.8 (CH2, C-5’), 22.3 (CH2, C-6’), 22.2 (CH2,
C-7’); mp: 177 ◦C; MS (ESI)m/z: calcd for C18H16F3NO4S,
399; found, 400 [M+H]+.
3.4.3 5-Bromo-2-(naphthalene-2-sulfonamido) benzoic
acid (11)
(0.13 g, 67 % yield) 1H-NMR (300 MHz, DMSO-d6): δ =
10.2 [s, 1H, COOH], 9.8 [s, 1H, NH] 8.59 [d, 4J1′,3′ =
1.4 Hz, 1H, 1’-HAr], 8.17 [d, 3J8′,7′ = 7.8 Hz, 1H, 8’-HAr],
8.10 [d, 3J4′3′ = 8.8 Hz, 1H, 4’-HAr], 8.02 [d, 3J5′,6′ =
7.8 Hz, 1H, 5’-HAr], 7.93 [d, 4J6,4 = 2.4 Hz, 1H, 6-HAr], 7.77
[dd, 3J3′,4′ = 8.8 Hz, 4J3′,1′ = 1.4 Hz, 1H, 3’-HAr], 7.72–7.65
[m, 3H, 4-HAr, 6’-HAr, 7’-HAr], 7.51 [d, 3J3,4 = 8.9 Hz, 1H,
3-HAr]. 13C-NMR (75 MHz, DMSO-d6): δ = 168.2 (C, C-
7), 138.8 (C, CAr-2), 136.8 (CH, CAr-4), 135.3 (C, CAr-4a’),
134.4 (C, CAr-8a’), 133.4 (CH, CAr-6), 131.4 (CH, CAr-6’),
129.3 (CH, CAr-4’), 128.5 (CH, CAr-8’), 127.8 (2×CH, CAr-
5’, CAr-7’) 121.6 (CH, CAr-3’), 120.6 (CH, CAr-3), 119.0 (C,
CAr-1), 114.9 (C, CAr-5). mp: 199 ◦C; (ESI) m/z: calcd for
C17H11BrNO4S−, 403.9560; found, 403.9613 [M−H]−.
3.4.4 5-Bromo-2-(phenylmethylsulfonamido)benzoic
acid (12)
(0.07 g, 42 % yield) 1H-NMR (300 MHz, DMSO-d6): δ =
10.57 [s, 1H, COOH ], 8.05 [d, 4J6,4 = 2.4 Hz, 1H, 6-HAr],
7.75 [dd, 3J4,3 = 8.9 Hz, 4J4,6 = 2.4 Hz, 1H, H-4Ar], 7.49 [d,
3J3,4 = 8.9 Hz, 1H, 3-HAr], 7.33–7.28 [m, 3H, 3’-HAr, 5’-
HAr], 7.23–7.20 [m, 2H, 4’-HAr], 5.75 [s, 1H, NH ], 4.72 [s,
2H, 1’-H]. 13C-NMR (75 MHz, DMSO-d6): δ = 168.3 (C,
C-7), 139.9 (C, CAr-2), 137(CH, CAr-4), 133.4 (CH, CAr-
6), 130.7 (CH, CAr-3’), 128.6 (C, CAr-2’), 128.4 (CH, CAr-
5’), 128.3 (CH, CAr-4’), 119.5 (CH, CAr-3), 117.5 (C, CAr-
1), 113.9 (C, CAr-5), 57.4 (CH2, C-1’). mp: 216 ◦C; (ESI)





(0.6 g, 29 % yield) 1H-NMR (300 MHz, DMSO-d6): δ =
7.97 [d, 4J6,4 = 2.4 Hz, 1H, 6-HAr), 7.85 (d, 3J2′,3′ = 8.3 Hz,
2H, 3’-HAr), 7.73 [dd, 3J4,3 = 8.9 Hz, 4J4,6 = 2.4 Hz, 1H, 4-
HAr], 7.63 [d, 3J2′,3′ = 8.3 Hz, 2H, 2’-HAr], 7.47 [d, 3J3,4 =
8.9 Hz, 1H, 3-HAr], 7.29 [dd, 3J3′′,2′′=3J3′′,4′′ = 7.3 Hz, 2H,
3”-HAr], 7.00–6.92 [m, 3H, 4”-HAr, 2”-HAr], 5.17 [s, 2H,
5’-H]. 13C-NMR (75 MHz, DMSO-d6): δ = 168.2 (C, C-
7), 157.9 (C, CAr-1”), 143.2 (C, CAr-4’), 138.8 (C, CAr-2),
137.5 (C, CAr-1’), 136.9 (CH, CAr-4) 133.5 (CH, CAr-6),
129.4(CH, CAr-3”), 128.1(CH, CAr-2’), 127.0 (CH, CAr-3’),
120.9 (CH, CAr-4”), 120.5 (CH, CAr-3), 119.0 (C, CAr-1),
114.9(CH, CAr-5), 114.7 (CH, CAr-2”), 68.0 (CH2, C-5’) mp:





(0.6 g, 78 % yield) 1H-NMR (300 MHz, DMSO-d6): δ =
11.77 [s, 1H, COOH], 9.98 [s, 1H, NH], 7.68 [d, 4J6,4 =
2.4 Hz, 1H, 6-HAr], 7.51 [dd, 3J4,3 = 7.1 Hz, 4J4,6 = 2.4 Hz,
1H 4-HAr], 7.17 [d, 2H, 4’-HAr, 6’-HAr], 7.14 [d, 3J3,4 = 1H,
3-HAr], 2.56 [s, 6H, CH3, 9’-H, 7’-H], 2.21 [s, 3H, CH3,
8’-H]. 13C-NMR (300 MHz, DMSO-d6): δ = 168.8 (C, C-
7), 143.3 (C, CAr-2), 139.5 (C, CAr-2’), 139.0 and 139.0
(2×C, CAr-3’, CAr-1’) 137.3 (CH, CAr-4), 134.0 (CH, CAr-
6’), 133.0 (CH, CAr-6), 132.5 and 132.5 (2×CH, CAr-4’,
CAr-6’) 119.1 (CH, CAr-3), 117.9 (C, CAr-5), 114.3 (C, CAr-
1), 22.5 and 22.5 (2×CH3, C-7’, C-9’) 20.7 (CH3, C-8’); mp:
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Scheme 3. Synthesis of compounds 8, 11–17.





(0.4 g, 63 % yield) 1H-NMR (300 MHz, DMSO-d6): δ =
12.28 [s, 1H, COOH]; 12.10 [s, 1H, NH], 8.11 [d, 4J6,4 =
2.5 Hz, 1H, 6-HAr], 8.08 [d, 3J3′2′ = 7.5 Hz, 2H, 3’-HAr],
7.86 [dd, 4J4,6 = 2.5 Hz, 3J4,3 = 7.3 Hz, 1H, 4-HAr], 7.64
[d, 3J4,3 = 7.3 Hz, 1H, 3-HAr], 7.56 [dd 3J2′,3′ = 7.5 Hz,
4J2′,6′ = 2.3 Hz, 2H, 2’-HAr, 6’-HAr] 7.22 [dd, 3J3′,2′ =
7.5 Hz, 4J3′,5′ = 2.1 Hz, 2H, 3’-HAr, 5’-HAr] 2.50 [s, 3H,
CH3, 8’-H]. 13C-NMR (75 MHz, DMSO-d6): δ = 197.9 (C,
C-7’), 169.1 (C, C-8), 151.8 (C, CAr-2) 143.5 (C, CAr-1’),
142.5 (C, CAr-4’), 140.6 (CH, CAr-4), 131.4 (CH, CAr-7),
129.6 (2×CH, CAr-3’, CAr-5’), 128.6 (2×CH, CAr-2’, CAr-
6’), 127.6 (C, CAr-6), 123.0 (C, C-Ar-5), 118.7 (CH, CAr-
3), 27.3 (CH3, C-8’); mp: 170 ◦C; MS (ESI) m/z: calcd for




(0.4 g, 65 % yield) 1H-NMR (300 MHz, DMSO-d6): δ =
11.48 [s, 1H, COOH], 8.13 [s, 1H, NH], 7.89 [d, 4J6,4 =
2.5 Hz, 1H, 6-HAr] 7.66 [dd, 3J4,3 = 8.1 Hz, 4J4,6 = 2.5 Hz,
1H, 4-HAr], 7.23 [d, 3J4,3 = 8.1 Hz 1H, 3-HAr], 7.11 [dd,
3J2′,3′ = 7.3 Hz, 4J2′,8′ = 3.2 Hz, 1H, 2’-HAr] 6.95 [ d,
4J2′,8′ = 3.2 Hz, 1H, 8’-HAr] 4.23–4.31 [m, 4H, 5’-H, 6’-H].
13C-NMR (75-MHz, DMSO-d6): δ = 168.9 (C, C-8), 148.3
(C, C-4’), 143.8 (C, C-2), 143.5 (C, C-7’), 131.3 (C, C-1’),
130.8 (CH, C-4), 128.6 (CH, C-6), 125.7 (C, C-7), 122.1
(C, C-5), 120.9 (CH, C-2’), 118.3 (CH, C-3), 118.1 (CH, C-
3’), 116.8 (CH, C-8’), 64.7 (CH2, C-5’) 64.3 (CH2, C-6’);





(0.38 g, 62 % yield) 1H-NMR (300 MHz, DMSO-d6): δ =
12.28 [s, 1H, COOH], 11.60 [s, 1H, NH], 8.15 [d, 4J6,4 =
2.1 Hz, 1H, 6-HAr] 7.92 [dd, 3J4,3 = 7.9 Hz, 4J4,6 = 2.1 Hz,
1H, 4-HAr] 7.87 [d, 4J6′,4′ = 1.9 Hz, 2H, 4’-HAr, 6’-HAr],
7.48 [d, 3J3,4 = 7.9 Hz, 1H, 3-HAr], 2.60 [s, 6H, CH3, 9’-H,
7’-H], 2.23 [s, 3H, CH3, 8’-H]. 13C-NMR (75 MHz, DMSO-
d6): δ = 169.3 (C, C-7), 154.2 (C, C-2), 143.6 (C, C-2’) ,
139.1 and 139.1 (2×C, C-1’, C-3’) 132.9 (C, C-5’), 132.5
(CH, C-4), 131.5 and 131.5 (2×CH, C-4’, C-6’), 130.1(CH,
C-6), 128.7 (C, C-8), 122.5 (C, C-5), 117.0 (CH, C-3), 109.0
(C, C-1), 22.4 and 22.4 (2×CH3, C-7’, C-9’), 20.8 (CH3, C-
8’); mp: 184 ◦C; MS (ESI) m/z: calcd for C17H16F3NO4S,
387; found, 388 [M+H]+.
18, 19, 20, and 21 were purchased from Enamine, Kiev,
Ukraine, as pure compounds (see also Table S6).
3.5 Determination of ligand binding and binding
constant by NMR
50 µM of 15N-labelled protein samples was prepared in a
20 mM sodium phosphate buffer containing 50 mM sodium
chloride, 0.02 % (w/v) NaN3, at pH 7.4. Stock solutions of
small molecules were prepared in DMSO-d6 at a concentra-
tion of 160 mM. A 1H−15N HSQC spectrum of Dvl PDZ was
acquired at 300 K with 5 % DMSO-d6 in the absence of lig-
and as reference spectrum. Mixtures of 16 compounds were
added to 15N-labelled Dvl PDZ at eightfold molar excess
each. The final concentration of DMSO-d6 in the protein–
Magn. Reson., 2, 355–374, 2021 https://doi.org/10.5194/mr-2-355-2021
N. Kamdem et al.: Small-molecule inhibitors of Dvl PDZ interrupt Wnt signalling 367
ligand solutions was 5 %. Spectra were acquired with eight
scans and 256 points in the indirect dimension.
Binding was deduced if the resonance position of a
cross peak was significantly shifted compared to the refer-
ence spectrum. The active compound was obtained through
successive deconvolution. Experiments were recorded on
a Bruker DRX600 spectrometer equipped with a triple-
resonance cryoprobe. The preparation of samples was done
automatically by a Tecan Genesis RSP 150 pipetting robot.
Spectra were analysed using the programs TOPSPIN and
SPARKY.
Chemical shift perturbations were obtained by comparing
the 1H−15N backbone resonances of protein alone to those
of protein–ligand complex. The mean shift difference (1δ
in ppm) was calculated using Eq. (1) (Garrett et al., 1997;










Here 1δN and 1δH are the amide nitrogen and amide proton
chemical shift differences between the free and the bound
states of the protein. In order to estimate binding constants,
titration experiments monitored by NMR were done. A se-
ries of 1H−15N HSQC were recorded as a function of ligand
concentration. Residues showing a continuous chemical shift
change and for which the intensity remained strong were
classified as being in fast exchange. The dissociation binding
constant was estimated by fitting the observed chemical shift






([LT] + [PT] +KD)2− 4[LT] · [PT]
2[PT]
(2)
1δ is the observed protein amide chemical shift change at a
given compound concentration, and 1δmax is the maximum
chemical shift change at saturation. [LT] is the total concen-
tration of the compound, and [PT] is the total concentration
of the protein. KD is the equilibrium dissociation constant.
The KD values are reported as means± standard deviations
of at least six residues influenced upon binding of the ligand.
3.6 Determination of binding constant by isothermal
titration calorimetry (ITC)
Isothermal titration calorimetry (ITC) experiments were
performed using a VP-ITC system (MicroCal). Protein in
20 mM HEPES buffer and 50 mM NaCl (pH 7.4) was cen-
trifuged and degassed before the experiment. A 200 µM lig-
and solution containing 2 % DMSO was injected 30 times
in 10 µL aliquots at 120 s intervals with a stirring speed of
1000 rpm into a 1.4 mL sample cell containing the Dvl PDZ
domain at a concentration of 20 µM at 25 ◦C. Control exper-
iment was initially determined by titrating ligand into buffer
at the same conditions. Titration of ligand into buffer yielded
negligible heat. Thermodynamic properties and binding con-
stants were determined by fitting the data with a non-linear
least-squares routine using a single-site binding model with
Origin (OriginLab) for ITC v.7.2 (MicroCal).
3.7 Protein expression
PDZ domains of human AF6 (P55196-2, residues 985–
1086) and murine α1-syntrophin (Q61234, residues 81–
164) were cloned into pGEX-6P-2 (Amersham Biosciences,
Freiburg, Germany) and pGAT2 (European Molecular Bi-
ology Laboratory, Heidelberg, Germany), respectively. Pro-
teins were expressed in E. coli BL21 (DE3) cells and puri-
fied as previously described (Boisguerin et al., 2004). For the
cloning of the Dvl-1 PDZ domain (O14640, residues 245–
338), IMAGp958J151157Q (ImaGenes) was used as tem-
plate. V250 is exchanged to isoleucine as in human Dvl-3
or murine Dvl-1. The C-terminal C338 of the domain was
exchanged by serine. Via cloning in pET46EK/LIC, a cod-
ing sequence for a TEV (tobacco etch virus) protease cleav-
age site was introduced. The resulting plasmid, pDVL1, was
transformed in E. coli BL21 (DE3). Expression on twofold
M9 minimal medium with 0.5 g L−1 15N NH4Cl as sole ni-
trogen source in shaking culture was done at 25 ◦C overnight
with 1 mM IPTG. A yield of 25 mg of pure Dvl-1 was ob-
tained from 1 L culture after IMAC, TEV protease cleavage,
a second IMAC, and gel filtration (Superdex 75). The protein
domain Dvl-1_245–338 was supplied for NMR in 20 mM
phosphate buffer, pH 7.4, and 50 mM NaCl.
The production of Dvl-3 (Q92997 residues 243–336),
mShank3 (Q4ACU6, residues 637–744) PDZ domains and
the three PDZ domains of PSD95 was described by Saupe et
al. (2011).
3.8 Crystallization and X-ray diffraction
The His-tagged cleaved human Dvl-3 PDZ domain was con-
centrated to 12–20 mg mL−1 in the presence of a fivefold mo-
lar excess of compounds 3, 5, 6, 7, 11, and 12. Crystals of
all complexes were grown at room temperature by the sit-
ting drop vapour-diffusion method. 200 nL Dvl-3/compound
solution was mixed with an equal volume of reservoir solu-
tion using the Gryphon (Formulatrix) pipetting robot. Crys-
tals of all complexes were grown to their final size within
4 to 14 d. The Dvl-3 PDZ domain crystallized in complex
with compounds 3 and 7 in crystallization condition 30 %
PEG 8000, 0.2 M ammonium sulfate, 0.1 M MES pH 6.5;
with compound 5 in 30 % PEG 8000, 0.1 M MES pH 5.5;
with compound 6 in 1.2 M ammonium sulfate, 0.1 M citric
acid pH 5.0; with compound 12 in 32 % PEG 8000, 0.2 M
ammonium sulfate, 0.1 M Na-cacodylate pH 6.0; with com-
pound 11 in 1 M ammonium sulfate, 1 % PEG 3350, 0.1 M
Bis-Tris pH 5.5; with compound 12 in 1.26 M sodium phos-
phate, 0.14 M potassium phosphate; and with compound 18
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in 1.5 M ammonium sulfate, 12 % glycerol, 0.1 M Tris-HCl
pH 8.5. The crystals were cryoprotected if necessary, for data
collection by soaking for a few seconds in precipitant solu-
tion containing 20 % (v/v) glycerol and subsequently frozen
in liquid nitrogen. Diffraction data were collected at 100 K at
beamline BL14.1 at the synchrotron radiation source BESSY,
Helmholtz-Zentrum Berlin, and processed with XDS.
3.9 Structure determination and refinement
Phases for the Dvl-3 PDZ domain in complex with com-
pound 3 were obtained by molecular replacement with
PHASER (McCoy et al., 2007) using the Xenopus laevis Di-
shevelled PDZ-domain structure (PDB code 2F0A) as a start-
ing model. The reasonable crystal packing and electron den-
sity allowed for further model and compound building using
the program COOT (Emsley and Cowtan, 2004) with itera-
tive refinement with REFMAC (Murshudov et al., 1997). All
further complex structures were obtained in the same way
but using the final refined compound-free Dvl-3-PDZ struc-
ture as model for molecular replacement. The Ramachandran
statistics were analysed by MolProbity (Chen et al., 2010)
for all complexes, and all crystallographic statistics are given
in Tables S2 and S3. Figures were prepared with PyMOL.
Atomic coordinates and structure factor amplitudes for DVL-
3 PDZ domain in complex with compounds 3, 5, 6, 7, 11, 12,
18 were deposited in the Protein Data Bank with accession
codes 6ZBQ, 6ZBZ, 6ZC3, 6ZC4, 6ZC6, 6ZC7, and 6ZC8,
respectively.
3.10 MTT assay
HEK293 cells were plated on a 96-well plate and treated with
different concentrations of Dvl inhibitors. After 24 h treat-
ment, 20 µL of MTT solution (5 mg mL−1) was added into
each well. After 2 h incubation, cell culture medium was re-
placed with 50 µL DMSO, and the signal of the purple for-
mazan, produced by living cells, was measured by a plate
reader.
3.11 TOP-GFP reporter assay
The lentivirus particle (CCS-018L, SABiosciences) encod-
ing GFP under the control of a basal promoter element
(TATA box) joined to tandem repeats of a consensus
TCF/LEF binding site was transfected into HEK293 cells.
Stable cells were selected by puromycin (2 µgmL−1) treat-
ment. Wnt signalling activity indicated by GFP intensity was
measured by flow cytometry after 24 h incubation with re-
combinant mouse Wnt3a (100 ng mL−1) or GSK3 inhibitor
CHIR99021 (3 µM) in the presence of Dvl inhibitors.
3.12 Luciferase reporter assays
Plasmids encoding a firefly luciferase reporter gene un-
der the control of different responsive elements were trans-
fected into HeLa cells with a pRL-SV40 normalization re-
porter plasmid using the Lipofectamine 2000 (Invitrogen).
After desired treatment, cells were harvested in the pas-
sive lysis buffer (Promega), and 15 µL cell lysate was trans-
ferred to 96-well LumiNunc plates (Thermo Scientific). Fire-
fly luciferase and Renilla luciferase were detected with the
D-luciferin buffer (75 mM HEPES, 4 mM MgSO4, 20 mM
DTT, 100 µM EDTA, 0.5 mM ATP, 135 µM Coenzyme A,
and 100 µM D-Luciferin sodium salt; pH 8.0) and the coe-
lenterazine buffer (15 mM Na4PPi, 7.5 mM NaAc, 10 mM
CDTA, 400 mM Na2SO4, 25 µM APMBT, and 1.1 µM coe-
lenterazine; pH 5.0), respectively, using the CentroXS LB960
lumiometer (Berthold Technologies).
3.13 Immunoblotting
To assess the β-catenin accumulation in HeLa cells, cells
were treated with Wnt3a in the presence of Dvl inhibitors for
24 h and lysed in RIPA buffer (50 mM Tris, pH 8.0, 1 % NP-
40, 0.5 % deoxycholate, 0.1 % SDS, 150 mM NaCl). Equal
amounts of protein were loaded on a SDS-PAGE. Separated
proteins were blotted onto PVDF membranes (polyvinyli-
dene fluoride) for immunoblot analysis using anti-β-catenin
antibody (610154, BD). HRP-conjugated anti-mouse anti-
body (715-035-150, Jackson ImmunoResearch Laboratories)
was used for secondary detection with Western lightning
chemiluminescence reagent plus (PerkinElmer) and Vilber
Lourmat imaging system SL-3.
3.14 qRT-PCR analysis
To measure the Wnt target accumulation at mRNA level,
HeLa cells were treated with Wnt3a in the presence of
Dvl inhibitors for 24 h. mRNA was extracted according
to the standard TRIzol® protocol (Invitrogen) and reverse-
transcribed using random primers (Invitrogen) and M-MLV
reverse transcriptase (Promega). The qRT-PCR was per-
formed in a iQ5 multi-colour real-time PCR detection sys-
tem (Bio-Rad) using SYBR® Green (Thermo Scientific) and
gene-specific primer pairs of Bmp2, Axin2, LEF1, and β-
actin (endogenous control).
3.15 Migration assay
Cell motility was assessed using 24-well trans-well as-
say (pore diameter: 8 µm, Corning). SW480WL cells were
seeded in the upper chamber in serum-free DMEM with
0.1 % BSA; 20 % serum was supplemented to medium in the
lower chamber. After incubation with Wnt3a in the presence
of Dvl inhibitors for 24 h, non-migrant cells were scraped off
using a cotton swab; the migrated cells on the filters were
stained with DAPI, photographed, and counted.
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3.16 Colon sphere culture
SW480WL cells were trypsinized into single cells, seeded
on 24-well cell culture plates, pre-coated with 250 µL poly-
HEMA (12 mg mL−1 in 95 % ethanol, Sigma) per well, and
incubated with Wnt3a in the presence of Dvl inhibitors in the
sphere culture medium (F12 :DMEM 1 : 1, 1× B-27 supple-
ment, 20 ng mL−1 EGF, 20 ng mL−1 FGF, 0.5 % methylcel-
lulose) for 10 d. Numbers of spheres were then counted under
the microscope.
4 Conclusions
In the present work, small molecules that bind to Dvl PDZ
in the one-digit micromolar range with considerable selec-
tivity have been developed by an extensive structure-based
design approach. With regards to the affinity determined by
ITC, compound 18 binds to Dvl-1 and Dvl-3 in vitro with
KD values of 2.4 and 9.4, respectively, comparing very well
with known ligands. X-ray structures of Dvl-3 PDZ com-
plexes with selected compounds provided insight into cru-
cial interactions and served as the basis for the design of
tight binding compounds with reduced toxicity. The struc-
tural investigations revealed that these compounds form hy-
drogen bonds with the amide groups of residues L260, G261,
and I262 in the PDZ-domain loop and the side chains of
residues H324 and R320. Finally, the chosen methodology,
i.e. virtual screening followed by a two-stage NMR-based
screening, X-ray crystallography, and chemical synthesis, is
an excellent path towards bioactive interaction partners. Our
best compounds effectively inhibited the canonical Wnt sig-
nalling pathway in a selective manner and could be devel-
oped for further studies.
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Appendix A: Abbreviations used
NMR, nuclear magnetic resonance
HSQC, heteronuclear single quantum correlation
AU, asymmetric unit
SAR, derive structure activity relationships
vdW, van der Waals
ITC, isothermal titration calorimetry
PDZ, PSD95/Disc large/Zonula occludens-1
Dvl, Dishevelled
PPI, protein–protein interactions
PDB, Protein Data Bank
CSP, chemical shift perturbation





qRT-PCR, quantitative real-time polymerase chain reaction
DMEM, Dulbecco’s modified Eagle’s medium
BSA, bovine serum albumin
TFA, trifluoroacetic acid
IPTG, isopropyl β-D-thiogalactopyranoside








XDS, X-ray Detector Software
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